how do glp-1 agonists work for diabetes and the kidney: from physiology to pharmacology and outcomes in How GLP-1 Receptor Agonists Evolved

Overall, use of GLP1-RA compared with the use of DPP-4i was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, CI 0.591.12)

A descriptive analysis evaluated report characteristics including demographics, outcomes, and indications, and identified the top 20 concomitant medications

While the contribution of weight loss remains unclear, this study, alongside emerging preclinical data from rodent models, suggests that GLP-1 medicines may offer efficacy in inflammation-driven diseases independent of the amelioration of metabolic dysfunction

day 4, 6 nmol/kg

Yet, for surgery candidates, integrate GLP-1s as bridges, not barriersmonitor progress rigorously to avoid cost traps

PubMed, Ding, Weiyue, et al